LOS ANGELES--(BUSINESS WIRE)--Nov. 8, 2005--Clearant, Inc. (OTCBB: CLRI), the developer of the patent-protected CLEARANT PROCESS(R) for pathogen inactivation, today announced that it has signed definitive agreements for a private sale of approximately 3.774 million shares of its common stock and warrants to purchase approximately 1.699 million additional shares of common stock for an aggregate purchase price of approximately $12.0 million.
